Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression
Open Access
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Psychiatry Research
- Vol. 296, 113649
Abstract
No abstract availableKeywords
Funding Information
- Myriad Genetics
This publication has 31 references indexed in Scilit:
- Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safetyExpert Opinion on Drug Metabolism & Toxicology, 2015
- Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypesThe Pharmacogenomics Journal, 2015
- Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient settingPharmacogenetics and Genomics, 2013
- Using a pharmacogenomic algorithm to guide the treatment of depressionTranslational Psychiatry, 2012
- Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacyEuropean Neuropsychopharmacology, 2012
- PharmGKB summaryPharmacogenetics and Genomics, 2011
- A standardized framework for the validation and verification of clinical molecular genetic testsEuropean Journal of Human Genetics, 2010
- Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D ReportAmerican Journal of Psychiatry, 2006
- The Metabolic Fate of Amitriptyline, Nortriptyline and Amitriptylinoxide in ManDrug Metabolism Reviews, 2004
- Tricyclic Antidepressant Concentrations in PlasmaJournal of Clinical Psychopharmacology, 1994